Glial fibrillar acidic protein in the cerebrospinal fluid of Alzheimer’s disease, dementia with Lewy bodies, and frontotemporal lobar degeneration

Cited by (156)

Items 101–156 of 156

1. Serum Levels of Clusterin, PKR, and RAGE Correlate with Amyloid Burden in Alzheimer’s Disease
   Paloma Monllor, Esther Giraldo, Mari-Carmen Badía, José García de la Asunción, Maria-Dolores Alonso, Ana Lloret, José Viña · 2021 · Journal of Alzheimer s Disease
2. Truncated TDP‐43 proteoforms diagnostic of frontotemporal dementia with TDP‐43 pathology
   Lauren M. Forgrave, Kyung‐Mee Moon, Jordan E. Hamden, Yun Li, Phoebe Lu, Leonard J. Foster, Ian R. Mackenzie, Mari L. DeMarco · 2023 · Alzheimer s & Dementia
3. CAR-T Cell Therapy-Related Neurotoxicity in Pediatric Acute Lymphoblastic Leukemia: Spectrum of Imaging Findings
   Ai Peng Tan · 2020 · Pediatric Neurology
4. Biomarkers in Parkinson’s Disease
   Sarah M. Brooker, Paulina González-Latapí · 2025 · Neurologic Clinics
5. Astrocyte Reactivity in Alzheimer’s Disease: Therapeutic Opportunities to Promote Repair
   Nazanin Mirzaei, Nicola Davis, Tsz Wing Chau, Magdalena Sastre · 2021 · Current Alzheimer Research
6. Fluid Biomarkers of Frontotemporal Lobar Degeneration
   Emma Louise van der Ende, John Cornelis Van Swieten · 2021 · Advances in experimental medicine and biology
7. Prognostic value of plasma glial fibrillary acidic protein in cognitively unimpaired older adults: Results from the A4 study
   Elham Ghanbarian, Tian-Chen Qian, B. Khorsand, Lu-Kai Zheng, S. A. Sajjadi, Joshua D. Grill, L. Rabin, R. Lipton, R. Sperling, A. Ezzati · 2025 · Alzheimer's & Dementia
8. Cerebrovascular disease drives Alzheimer plasma biomarker concentrations in adults with Down syndrome
   Natalie C. Edwards, Patrick J. Lao, Mohamad J. Alshikho, Olivia M. Ericsson, Batool M. Rizvi, Melissa E. Petersen, Sid E. O’Bryant, Lisi Flores Aguilar, Sabrina Simoes, Mark E. Mapstone et al. · 2023 · medRxiv
9. Biomarcadores en sangre para la enfermedad de Alzheimer: posicionamiento y recomendaciones de uso del Grupo de Estudio de Conducta y Demencias de la Sociedad Española de Neurología
   Marc Suárez‐Calvet, Carla Abdelnour Ruiz, Daniel Andres Alcolea, Maite Mendióroz, Mircea Balasa, Estrella Morenas‐Rodríguez, Albert Puig‐Pijoan, Pascual Sánchez‐Juan, Alberto Villarejo‐Galende, Raquel Sánchez‐Valle · 2024 · Neurología
10. Cerebrospinal fluid transcripts may predict shunt surgery responses in normal pressure hydrocephalus
    Zachary Levin, Owen P. Leary, Victor Mora, Shawn Kant, Sarah Brown, Konstantina A. Svokos, Umer Akbar, Thomas Serre, Petra Margarete Klinge, Alexander Fleischmann et al. · 2023 · Brain
11. Alzheimer’s disease: a scoping review of biomarker research and development for effective disease diagnosis
    Khushboo Govind Faldu, Jigna Shah · 2022 · Expert Review of Molecular Diagnostics
12. Blood-based biomarkers for Alzheimer's disease: positioning document and usage recommendations from the Behavioral Neurology and Dementia Study Group of the Spanish Society of Neurology
    Marc Suárez‐Calvet, Carla Abdelnour Ruiz, Daniel Andres Alcolea, Maite Mendióroz, Mircea Balasa, Estrella Morenas‐Rodríguez, Albert Puig‐Pijoan, Pascual Sánchez‐Juan, Alberto Villarejo‐Galende, Raquel Sánchez‐Valle · 2025 · Neurología (English Edition)
13. Effects of anti‐tau immunotherapy on reactive microgliosis, cerebral endotheliopathy, and cognitive function in an experimental model of cerebral malaria
    Oscar Bate Akide Ndunge, Henry J. Shikani, Minxian Dai, Brandi D. Freeman, Mahalia S. Desruisseaux · 2023 · Journal of Neurochemistry
14. Persistent delirium is associated with cerebrospinal fluid markers of neuronal injury
    Alex Tsui, Benjamin Johnstone, Amanda Heslegrave, Henrik Zetterberg, Leiv Otto Watne, Bjørn Erik Neerland, Maria Krogseth, Colm M. Cunningham, Alasdair M. J. MacLullich, Graciela Muniz Terrera et al. · 2024 · Brain Communications
15. Biomarkers and Their Implications in Alzheimer’s Disease: A Literature Review
    Vincent Marcucci, Jeremy Kleiman · 2021 · Exploratory Research and Hypothesis in Medicine
16. Immunological Fluid Biomarkers in Frontotemporal Dementia: A Systematic Review
    Philip Ahle Erichsen, Emil Elbæk Henriksen, Jørgen Erik Nielsen, Patrick Ejlerskov, Anja Hviid Simonsen, Anders Dyhr Toft · 2025 · Biomolecules
17. The potential of serum S100 calcium-binding protein B and glial fibrillary acidic protein as biomarkers for traumatic brain injury
    Seke Nzau Mafuika, Thajasvarie Naicker, Rohen Harrichandparsad, Lelika Lazarus · 2022 · Translational Research in Anatomy
18. Serum neurofilament light is superior to glial fibrillary acidic protein to distinguish sporadic frontotemporal dementia from late-onset primary psychiatric disorders: a retrospective DIPPA-FTD study
    Sterre C.M. de Boer, Chiara Fenoglio, Andrea Arighi, Lisa Wissink, Lina Riedl, Ishana Rue, Ramón Landín-Romero, Sophie Matis, Zac Chatterton, Glenda Margaret Halliday et al. · 2025 · BMJ Neurology Open
19. Glial fibrillary acidic protein in cerebrospinal fluid in humans is sensitive to various pre-analytical conditions: possible explanation and solution
    Björn Evertsson, Ingela Nilsson Remahl, Max Albert Hietala, Anja Finn · 2025 · Frontiers in Neurology
20. Biomarkers of diagnosis, prognosis, pathogenesis, response to therapy: Convergence or divergence? Lessons from Alzheimer's disease and synucleinopathies
    Stefano Luca Sensi, Mirella Russo, Pietro Tiraboschi · 2023 · Handbook of clinical neurology
21. Plasma GFAP outperforms CSF GFAP in detecting amyloid pathology and is associated with increased risk of clinical progression in early Alzheimer’s disease
    Arda Can Cetindag, Carola G. Schipke, Hermann Esselmann, Niels Kruse, Jens Wiltfang, Anja Schneider, Klaus Fließbach, Carolin Miklitz, Franziska Maier, Katharina Büerger et al. · 2026 · The Journal of Prevention of Alzheimer s Disease
22. Development of Optical Biosensors for Diagnosis of Amyloid- β Peptide and Glial Fibrillary Acidic Protein
    Riddhi Garg, Kashish Parwani, Renu Bist · 2023 · Journal of Analysis and Computations
23. Analysis of brain atrophy and local gene expression in genetic frontotemporal dementia
    André Altmann, David M. Cash, Martina Bocchetta, Carolin Heller, Regina Hertfelder Reynolds, Katrina M. Moore, Rhian S. Convery, David Lee Thomas, John Cornelis Van Swieten, Fermín Moreno et al. · 2019 · bioRxiv (Cold Spring Harbor Laboratory)
24. CSF biomarkers of neurotoxicity in childhood cancer survivors after cranial radiotherapy or surgery
    Erik Fernström, Marianne Jarfelt, Malin Blomstrand, Birgitta Lannering, Markus Axelsson, Pontus Wasling, Thomas Björk‐Eriksson, Henrik Zetterberg, Marie Kalm · 2024 · Annals of Clinical and Translational Neurology
25. The relevance of combined testing of cerebrospinal fluid glial fibrillary acidic protein and ubiquitin C-terminal hydrolase L1 in multiple sclerosis and peripheral neuropathy
    Péter Csécsei, Péter Ács, Marianna GOTTSCHAL, Piroska Imre, Egon Miklos, Diána Simon, Szabina Erdő-Bonyár, Tímea Berki, László Závori, Réka Várnai · 2024 · Neurological Sciences
26. Fluid Markers of Alzheimer Disease
    Courtney L. Sutphen, Katherine Volluz, Rawan M. Tarawneh · 2025 · Springer eBooks
27. CSF markers of neuroinflammation, synaptic dysfunction and [18F]DOPA-PET in Parkinson's disease
    Kevin Oliveira Hauer, Sara Hall, Adjmal Nahimi, Olof T. Strandberg, Tomas G. Ohlsson, Jonas Jögi, Erik Stomrud, Shorena Janelidze, Oskar Hansson, Ruben A Smith · 2025 · Parkinsonism & Related Disorders
28. Glial and neuronal cell-free DNA in plasma of sporadic bvFTD and late onset primary psychiatric disease patients
    Zac Chatterton, Sterre C.M. de Boer, Lina Riedl, Sophie Matis, Chiara Fenoglio, Ishana Rue, Ramón Landín-Romero, Dean Southwood, Daniela Galimberti, Andrea Arighi et al. · 2025 · Scientific Reports
29. Limited Diagnostic Performance of Cerebrospinal Fluid Glial Fibrillary Acidic Protein in Dementia
    Pontus Erickson, Tobias Borgh Skillbäck, Silke Kern, Ingmar Gr. Skoog, Linus Jönsson, Ulf Andréasson, Kaj Blennow, Maria Eriksdotter, Henrik Zetterberg · 2026 · Dementia and Geriatric Cognitive Disorders
30. CSF and plasma GFAP and VEGF in adult type 3 spinal muscular atrophy patients treated with nusinersen
    Ana Catarina Pronto‐Laborinho, Teresa Freitas, Sara Domingues, Michele Gomes Rosa, M. Viseu De Carvalho, Miguel Oliveira Santos · 2026 · Journal of the Neurological Sciences
31. Single- versus two-test criteria for cognitive impairment: associations with CSF and imaging markers in former American football players
    Monica T. Ly, Caroline Altaras, Yorghos Tripodis, Charles H. Adler, Laura Joan Balcer, Charles B. Bernick, Henrik Zetterberg, Kaj Blennow, Elaine R. Peskind, Sarah Jane Banks et al. · 2025 · The Clinical Neuropsychologist
32. Astrocytes and the Synucleinopathies
    Andrew O. Koob, Paola Sacchetti · 2018 · Springer eBooks
33. A pilot study of associations of markers of glial and neuronal degeneration with executive functions in alcohol use disorders
    Галкин Станислав Алексеевич, Lyudmila A. Levchuk, Svetlana А. Ivanova, Nikolay A. Bokhan · 2024 · S S Korsakov Journal of Neurology and Psychiatry
34. Fully Automated Measurement of GFAP in CSF Using the LUMIPULSE® System: Implications for Alzheimer’s Disease Diagnosis and Staging
    Hisashi Nojima, Mai Yamamoto, Jo Kamada, Tomohiro Hamanaka, Katsumi Aoyagi · 2025 · International Journal of Molecular Sciences
35. Role of astrocyte biomarker GFAP in early diagnosis and prognosis assessment of dementia: A comprehensive review
    Shengxi Li, Shufei Wei, Ling Wang, Tianrui Yu, Huaying Wang, Seung Bum Yang, Wa Cao, Xiaorong Zhang · 2026 · International Journal of Biological Macromolecules
36. Glial fibrillary acidic protein (GFAP) in biofluids: analytical considerations and clinical relevance in neurodegenerative diseases
    Aurélie Hanin, Isabelle Quadrio, Jean‐Louis Beaudeux, Foudil Lamari · 2026 · Journal of Neurology
37. Emerging biomarkers for Parkinson's disease in biological fluids
    Petra Bago Rožanković, Goran Šimić · 2026 · Frontiers in Aging Neuroscience
38. How do energy metabolism disorders and neuroinflammation collectively contribute to the pathogenesis of Alzheimer’s disease?
    Yinuo Lei, Liyang Liu, Yi Tang · 2026 · Ageing Research Reviews
39. Profit vs. nonprofit: does either have a competitive edge?
    D Mangan · 1998 · PubMed
40. The potential use of plasma GFAP as a diagnostic and prognostic biomarker of motor subtype in early Parkinson’s disease
    N. Che, R. Ou, C. Li, Li Zhang, Qun Wei, Si Wang, Quan Jiang, T. Yang, Yang Xiao, J. Lin et al. · 2024 · Parkinsonism & Related Disorders
41. Fluid and Imaging Markers of Frontotemporal Lobar Degeneration
    Fieke Prinse, Julie F. H. De Houwer, Elise G.P. Dopper, Harro Seelaar · 2025 · Springer eBooks
42. Promising Diagnostic Accuracy of Plasma GFAP and NfL Within The AD Continuum
    Tandis Parvizi, Theresa Koenig, Raphael Wurm, Sara Silvaieh, Patrick Altmann, Sigrid Klotz, Paulus Stefan Rommer, Julia Furtner, Günther Regelsberger, Johann P. Lehrner et al. · 2021 · Research Square
43. Headbutting goats self-inflict traumatic brain injury
    Ayodele Oyadeyi, Caroline Smith, Bridget V. Willeford, Gretchen Grissett-Hardwick, Kristen M. Fizzano, Robinson Ws, Anna G. Sorace, Andrea Osborne, S Samuel, Ian Campbell et al. · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
44. Assessment of the visual thalamic circuitry in hallucinations in dementia with Lewy bodies
    Daniel Erskine · 2017
45. Brain cross-omics integration in Alzheimer’s disease
    Abdallah M. Eteleeb, Brenna C. Novotny, Carolina Soriano‐Tárraga, Christopher Sohn, Eliza Dhungel, Logan Brase, Aasritha Nallapu, Jared Buss, Fabiana Farias, Kristy Bergmann et al. · 2022 · medRxiv
46. Breaking the amyotrophic lateral sclerosis early diagnostic barrier: the promise of general markers
    Yizhou Lu, Lu He, Huanyu Meng, Sheng Chen, Qinming Zhou · 2023 · Exploration of Neuroprotective Therapy
47. Fluid and Imaging Markers of Glial Reactivity
    Marc Suárez‐Calvet · 2025 · Springer eBooks
48. Biomarkers as Outcome Measures in Clinical Trials of Alzheimer Disease
    Rawan M. Tarawneh · 2025 · Springer eBooks
49. Additional file 1 of Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology
    Inge M.W. Verberk, Elisabeth H. Thijssen, Jannet Koelewijn, Kimberley Mauroo, Jeroen Vanbrabant, Arno de Wilde, Marissa Deborah Zwan, Sander C.J. Verfaillie, Rik Ossenkoppele, Frederik Barkhof et al. · 2020 · Figshare
50. Additional file 2 of Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia
    Nuole Zhu, Miguel Santos‐Santos, Ignacio Illán‐Gala, Víctor Montal, Teresa Estellés, Isabel Barroeta, Miren Altuna, Javier Arranz, Laia Muñoz, Olivia Belbin et al. · 2021 · Figshare
51. Additional file 1 of Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia
    Nuole Zhu, Miguel Santos‐Santos, Ignacio Illán‐Gala, Víctor Montal, Teresa Estellés, Isabel Barroeta, Miren Altuna, Javier Arranz, Laia Muñoz, Olivia Belbin et al. · 2021 · Figshare
52. Étude des perturbations astrocytaires sous l’influence de l’apolipoprotéine E4 : implications et applications dans la maladie d’Alzheimer
    Laurie Arnaud · 2021 · theses.fr (ABES)
53. Développement d’outils pour la caractérisation de la TDP-43 et exploration de marqueurs indirects dans un contexte de dégénérescence lobaire frontotemporale
    Jean Escal · 2021 · theses.fr (ABES)
54. Quantitative MRI Measurements of The Brainstem and Spinal Cord in Predicting Motor and Respiratory Capacity in Amyotrophic Lateral Sclerosis
    Mohammed Khamaysa · 2023 · theses.fr (ABES)
55. Plasma Alzheimer Biomarkers and Diagnostic Decision-Making in Memory Clinics
    Sinthujah Vigneswaran, Inge M.W. Verberk, Lynn Boonkamp, Lisanne in ‘t Veld, Marleen J. A. Simmelink, Daniel Antwi‐Berko, L. van Unen, Rebecca Z. Rousset, Thomas Claessen, Marissa Deborah Zwan et al. · 2026 · JAMA Network Open
56. Nanotechnology-enabled delivery of bioactive compounds for neuroprotection in Parkinson’s disease: mechanisms and future directions
    Praveen Kumar Gaur, Prachee Raje Bisht, Sonia Lal Gupta · 2026 · Journal of Biomaterials Science Polymer Edition